CER Daily Newsfeed

Value Viewpoint, Live From #ISPORAnnual: May 15, 2025

(5/15, Kimberly Westrich, LinkedIn) comments “...[T]omorrow [James Motyka] will present the award-winning poster ‘Ongoing Accelerated Approval Trends and What It Means for Patients.’ This work was honored as a Top 5% finalist for the ISPOR 2025 Research Presentation award. It provides a critical analysis of payer exclusions on non-oncology accelerated approval drugs, finding potentially devastating consequences for patients with high unmet need.” Full

Spotlighting Innovations in Pulmonary Care at ATS 2025

(5/16, Hayden E. Klein, The American Journal of Managed Care) reports “...AstraZeneca is expected to present more than 75 abstracts at the meeting, including 8 late-breaking studies focused on asthma, COPD, and rare eosinophilic disorders. Notable among these is the phase 3b BATURA study evaluating whether albuterol/budesonide (Airsupra), a fixed-dose albuterol/budesonide rescue therapy, can reduce cumulative exposure to systemic corticosteroids in patients with mild asthma compared with albuterol alone.” Full

Will International Prices Influence Medicare Price Negotiation?

(5/15, Cathy Kelly, Pink Sheet) reports “The Trump Administration is unlikely to incorporate international reference pricing into the Medicare price negotiation program unless it is designed as a demonstration project, former US Centers for Medicare and Medicaid Services official Kristi Martin suggested...Martin said during the ISPOR 2025 conference that adding international price considerations to the program would involve significant legal and operational challenges.” Subscription Required

UK: NICE Recommends Two Monoclonal Antibody Treatments

(5/16, Dr Rob Hicks, Medscape) reports “...Spesolimab has been endorsed for treating generalised pustular psoriasis (GPP). Atezolizumab has been recommended as adjuvant therapy for non–small-cell lung cancer (NSCLC).” Full

Health Technology Assessment – Challenges and Opportunities for Developers

(5/16, Stephen Corson, PharmaPhorum) comments “...JCAs have the potential to streamline the clinical assessment process, reduce duplication of efforts, and shorten the time to market for healthcare innovations. This should not only help to ensure healthcare resources are used more effectively, but also improve access to innovative treatments for patients. However, this shift will also see developers facing new challenges, including shorter submission timelines and extensive evidence requirements. Understanding key components of the new HTA and maintaining flexibility in data analysis processes is crucial as developers prepare for the changes ahead.” Full